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1
Inaddition to apolipoprotein E(APOE),recent large genome-wide association studies (GWASs)haveidentiﬁednine othergenes/
loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7) for late-onset Alzheimer’s disease (LOAD).
However, the genetic effect attributable to known loci is about 50%, indicating that additional risk genes for LOAD remain to be
identiﬁed. In this study, we have used a new GWAS data set from the University of Pittsburgh (1291 cases and 938 controls) to
examine in detail the recently implicated nine new regions with Alzheimer’s disease (AD) risk, and also performed a meta-
analysis utilizing the top 1% GWAS single-nucleotidepolymorphisms (SNPs) withPo0.01 along with four independent data sets
(2727 cases and 3336 controls) for these SNPs in an effort to identify new AD loci. The new GWAS data were generated on the
Illumina Omni1-Quad chip and imputed at B2.5 million markers. As expected, several markers in the APOE regions showed
genome-wide signiﬁcant associations in the Pittsburg sample. While we observed nominal signiﬁcant associations (Po0.05)
either within or adjacent to ﬁve genes (PICALM, BIN1, ABCA7, MS4A4/MS4A6E and EPHA1), signiﬁcant signals were observed
69–180kb outside of the remaining four genes (CD33, CLU, CD2AP and CR1). Meta-analysis on the top 1% SNPs revealed a
suggestive novel association in the PPP1R3B gene (top SNP rs3848140 with P¼3.05E–07). The association of this SNP with AD
risk was consistent in all ﬁve samples with a meta-analysis odds ratio of 2.43. This is a potential candidate gene for AD as this is
expressed in the brain and is involved in lipid metabolism. These ﬁndings need to be conﬁrmed in additional samples.
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Introduction
Alzheimer’s disease (AD), especially the late-onset form
(LOAD), is a complex multifactorial neurodegenerative
disease and the leading cause of dementia among the
elderly people.
1 Currently, there are B5 million AD cases in
the United States and about 35 million cases worldwide.
2 Due
to its long clinical course, AD is a major public health problem.
Genetic susceptibility at multiple genes and interactions
among them and/or environmental factors likely inﬂuence
the risk of AD. AD has a strong genetic basis with heritability
estimates up to 80%.
3 However, genetic variants in the four
well-established genes for AD; amyloid precursor protein and
presenilin 1 and 2 (PSEN1 and PSEN2) for the rare early-
onset, and apolipoprotein E (APOE) for the common LOAD
explain less than half of this heritability.
To identify the remaining genes for the common LOAD,
efforts have been focused on conducting genome-wide
association studies (GWASs)
4–11 because this approach is
hypothesis free and conceptually would identify all known and
unknown genes. However, with the exception of the APOE
region, no other signiﬁcant associations were replicated
across these initial GWAS. This highlights the difﬁculties in
identifying the remaining LOAD genes that are thought to
make a relatively small contribution to the overall risk
of disease and thus would require much large sample size
than used in earlier GWASs.
4–11 Recent large GWASs have
identiﬁed nine additional genes/loci for LOAD, including CR1,
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12–16 Although up to
80% of the AD risk is attributable to genetic factors,
3 all
of the known LOAD genes (including APOE and new ones)
account for about 50% of the total genetic variance. This
indicates that additional risk genes for LOAD remain to be
identiﬁed.
In this study, we used 2229 samples from the University of
Pittsburgh Alzheimer’s Disease Research Center (ADRC)
that were genotyped using the Illumina Omni1-Quad chip to
examine the extent of associations of the recently implicated
nine non-APOE risk loci for LOAD in this sample. In addition,
we performed a GWAS analysis in the Pittsburgh sample and
conducted a meta-analysis on the top 1% single-nucleotide
polymorphisms (SNPs) by incorporating additional 2727
cases and 3336 controls from prior studies to identify new
loci for AD.
Subjects and methods
Stage 1 sample. Genomic DNA from 1440 AD cases
and 1000 controls were genotyped using the Illumina
Human Omni1-Quad as part of the stage 1 discovery
sample. All subjects were European Americans. AD cases
(mean age-at-onset (AAO) 72.6±6.4 years; 65.6% women;
23.5% autopsy-conﬁrmed) were derived from the University
of Pittsburgh ADRC, all of whom met the National Institute
of Neurological and Communication Disorders and Stroke
(NINCDS)/Alzheimer’s Disease and Related Disorders
Association (ADRDA) criteria for probable or deﬁnite AD.
The University of Pittsburgh ADRC follows a standard evalu-
ation protocol, including medical history, general medical and
neurological examinations, psychiatric interview, neuro-
psychological testing and magnetic resonance imaging
scan. Controls were cognitively normal subjects that were
recruited from the same geographical area as the cases.
They were 60 years or older (mean age 74.07±6.20 years;
59.8% women; 0.2% autopsy-conﬁrmed), had no psychiatric
or neurological disorders, and did not meet criteria for mild
cognitive impairment or dementia. All subjects were recruited
with informed consent, and the study was approved by the
University of Pittsburgh Institutional Review Board.
Stage 2 samples. A total of 2727 cases and 3336 controls
were derived from four prior studies and they are brieﬂy
described below.
Mayo sample. The Mayo sample comprised 844 AD cases
(mean AAO: 74±4.8 years; 57.2% women) and 1255
controls (mean age: 73.2±4.4 years; 51.7% women) that
were previously genotyped using the Illumina HumanHap300
BeadChip.
11 AD diagnosis was established using the
NINCDS/ADRDA criteria.
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
sample. This data set consisted of 188 AD cases with a
clinical diagnosis of AD at baseline visit and 193 controls
(mean age: 78.6±5.3 years; 46.3% women) that were pre-
viously genotyped using the Illumina 610-Quad BeadChip.
17
AD cases were between the ages of 55 and 90 (mean AAO:
71.9±8.1 years; 44.6% women) and met NINCDS/ADRDA
criteria for AD. Details of the clinical evaluation and sample
characterization are described elsewhere.
18,19 The ADNI data
used in this report were obtained from the ADNI database
(adni.loni.ucla.edu). The initial goal of ADNI was to recruit
800 adults, aged 55–90, to participate in research on the
sensitivity and speciﬁcity of neuroimaging and other bio-
markers for detecting and monitoring AD pathology in vivo.
In ADNI, B200 cognitively normal older individuals and 400
people with amnestic mild cognitive impairment were followed
for 3 years and 200 people with mild early-stage AD who
were followed for 2 years. For up-to-date information, see
http://www.adni-info.org.
University of Miami/Vanderbilt University/Mt. Sinai School
of Medicine sample. The University of Miami/Vanderbilt
University/Mt. Sinai School of Medicine data set contains
1186 cases (mean AAO: 74.1±7.8 years; 64% women) and
1135 controls (mean age: 74.0±8.3; 61% women) ascer-
tained at the University of Miami, Vanderbilt University and
Mt. Sinai School of Medicine. Cases met NINCDS/ADRDA
criteria for probable or deﬁnite AD with AAO 460 years.
Cognitively healthy controls were unrelated individuals from
the same catchment areas.
16
MIRAGE study sample. MIRAGE is a family-based genetic
epidemiological study of AD that enrolled AD cases and
unaffected sibling controls at 17 clinical centers in the United
States, Canada, Germany and Greece. Brieﬂy, families
were ascertained through a proband meeting the NINCDS/
ADRDA criteria for deﬁnite or probable AD. Unaffected
sibling controls were veriﬁed as cognitively healthy based
on a Modiﬁed Telephone Interview of Cognitive Status
score of X86. For this study, we used 1262 subjects
(509 cases and 753 controls)
16 from the MIRAGE
Caucasian data set.
Genotyping and quality control of genotype data in the
Pittsburgh sample. The stage 1 Pittsburgh sample was
genotyped using the Illumina Omni1-Quad chip (containing
probes for 1016423 SNPs and/or copy-number variations) at
the Feinstein Institute of Medical Research (Manhasset, NY).
Genotypes for two APOE SNPs rs429358 (E*4) and rs7412
(E*2) were determined either as previously described
20 or
using TaqMan SNP genotyping assays.
Exclusion criteria for individual samples included consent
anddiagnosticcriteria(ﬁvecontrolswereexcludedbecauseof
updated diagnostic criteria, or refusal to participate further in
this study), high genotype failure rate (141 individuals were
removedbecause of a genotype failure rate 42%) and cryptic
relatedness (65 individuals were removed because they
displayed an average degree of sharing (identity by state or
IBS) 40.4 with other members of the data set). Exclusion
criteria for markers included minor allele frequency (189727
SNPs were removed because of minor allele frequency o1%),
deviation from Hardy–Weinberg expectations in controls (2239
SNPs gave a Hardy–Weinberg expectations test P-value
p1E–06), and high genotype failure rates (22385 SNPs were
removed because of genotype failure rates 42%). The ﬁnal
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cases and 938 controls.
Imputation. Genotype posterior probabilities were imputed
with MACH v.1.0 (http://www.sph.umich.edu/csg/abecasis/
MACH/), on all data sets using haplotypes from the HapMap
CEU v3 data release as a reference sample. The imputation
generated data for 43 million SNPs that were subsequently
ﬁltered to exclude SNPs with r2o0.3 and 2543888 were
included in the analysis. Additional details of the imputation
procedure were published previously.
16
Population stratiﬁcation. Population stratiﬁcation was exa-
mined using a multi-dimensional scaling method as imple-
mented in PLINK.
21 Four components were conservatively
determined to be relevant to the determination of population
origin based on the visual examination of principle compo-
nent plots.
Association analyses. Initial association analysis was per-
formed in the University of Pittsburgh ADRC’s GWAS data
set. After standard quality control ﬁlters for both genotypes
and samples and imputing for unobserved genotypes, a total
of B2.5 million SNPs were examined in 2229 subjects (1291
cases and 938 controls) for association analysis. Association
of SNPs with AD risk was tested using logistic regression
under an additive model that included age, sex and the ﬁrst
four principal components as covariates. All SNPs with P-
values of o0.01 were carried forward to the meta-analysis.
Signiﬁcance values from logistic regression analyses were
used for ranking purposes only, and so were not adjusted for
multiple testing. All analyses were done in R and/or PLINK.
Meta-analysis was done using a ﬁxed-effect methodology,
as implemented in PLINK. Heterogeneity testing was accom-
plished using Cochran’s Q statistic, summarized as the
I
2 statistic (the percentage of total variation across studies
that is due to heterogeneity rather than chance).
22,23 Values
closer to 0 indicate no heterogeneity, whereas larger
numbers indicate increasing degrees of heterogeneity
between studies.
Results
Association analysis in nine non-APOE AD loci. We ﬁrst
examined the association signals in the Pittsburgh
GWAS data in recently reported nine non-APOE AD gene
regions (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E,
CD2AP, CD33, EPHA1 and ABCA7)
12–16 in 2229 cases
and controls that passed quality control for both genotypes
and samples and included imputed data for unobserved
genotypes. Although this sample was included as one of
several replication samples in one GWAS that reported the
latter ﬁve gene region,
16 the extent of replications in these
ﬁve and the other four regions in this sample has previously
not been examined closely. We observed signiﬁcant asso-
ciations (Po0.05) either within or adjacent to ﬁve genes
(PICALM, BIN1, ABCA7, MS4A4/MS4A6E and EPHA1). On
the other hand, signiﬁcant signals were observed 69–180kb
outside of the remaining four genes (CD33, CLU, CD2AP
and CR1). The regional association plots containing SNPs
within B500kb on either side of these nine genes are
presented in Supplementary Figures 1–9.
In the PICALM gene and its surrounding sequence, 69
SNPs showed signiﬁcant associations (Supplementary
Figure 1). The top 11 SNPs with PoE–03 were located
in four different introns of the PICALM gene. The most
signiﬁcant SNP, rs17817992 (P¼1.37E–04), was located in
intron 2 followed by rs12790526 (P¼1.43E–04) in intron 2,
rs12795381 (P¼1.68E–04) in intron 12 and rs12802399
(P¼1.72E–04) in intron 2. The originally reported genome-
wide signiﬁcant SNP/rs3851179,
13 which is present about
89kb 50 to PICALM, was observed at P¼4.6E–02 in our
sample. In the BIN1 gene, 17 SNPs showed signiﬁcant
associations(SupplementaryFigure2),mostlyinthe50region,
including the 5 top signiﬁcant SNPs/rs11680911 (P¼2.9E–
04), rs7561528 (P¼3.0E–04), rs6743470 (P¼1.18E–03),
rs17014923 (P¼1.64E–03) and rs9394826 (P¼2.15E–03).
AmongourtopﬁvesigniﬁcantSNPs,rs7561528wasgenome-
wide signiﬁcant in the discovery sample of the Alzheimer
Disease Genetics Consortium.
16 The originally reported
genome-wide signiﬁcant SNP/rs744373 in the initial GWAS
after stage 3 meta-analysis
14 was observed at P¼1.02E–02
in our sample. In the ABCA7 gene, seven SNPs showed
signiﬁcant association (Supplementary Figure 3), including
the two most signiﬁcant SNPs, rs4147916 in intron 34
(P¼3.18E–03) and rs4147918 in exon 37 (P¼3.19E–03)
that is associated with an amino-acid change(Gln-Arg). The
reported genome-wide signiﬁcant SNP (rs3764650)
15 gave a
non-signiﬁcant but similar trend of association in our sample
(P¼1.68E–01).
There are multiple genes in the MS4A gene clusters on
chromosome 11. While one GWAS reported genome-wide
signiﬁcant SNPs in the MS4A4A gene,
16 another GWAS
found genome-wide signiﬁcant SNPs in the MS4A6A and
MS4A4E genes.
15 In our data set, we found a total of 39
SNPs with Po0.05 in the MS4A gene cluster (Supplementary
Figure 4) and the 5 most signiﬁcant SNPs were located
in the MS4A4A gene and its surrounding sequence:
rs11827324 (P¼2.58E–03), rs4939338 (P¼3.39E–03),
rs10792263 (P¼4.85E–03), rs11824773 (P¼8.06E–03)
and rs11824734 (P¼6.93E–03). The genome-wide signiﬁ-
cant SNP in the Alzheimer Disease Genetics Consortium
(rs4938933) gave the same trend of association in our sample
(P¼8.80E–02). There were eight signiﬁcant SNPs in the
EPHA1 gene (Supplementary Figure 5), including the top
signiﬁcant SNPs: rs10241042 (P¼2.27E–03), rs1525119
(P¼1.02E–02) and rs10233030 (P¼1.29E–02). The re-
ported genome-wide signiﬁcant SNP (rs11767557)
15,16 was
observed with a similar trend of association in our sample
(P¼1.11E–01).
For the other four genes, signiﬁcant SNPs (Po0.05) were
observed 69, 125, 143 and 180kb outside of the CD33, CLU,
CR1 and CD2AP genes, respectively. There were four SNPs
with Po0.05 and another seven with P-values between 0.05
and 0.10 located in an intergenic region about 69kb distal to
the CD33 gene. Likewise, there were four signiﬁcant SNPs
(P¼0.012–0.027) about 125kb proximal to the CD33 gene
(Supplementary Figure 6). The reported genome-wide
GWAS of AD
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15,16 gave a non-signiﬁcant but
similar trend of association in our sample (P¼2.50E–01).
Overall, recombination was found to be low in this region. In
the CLU region, 41 signiﬁcant SNPs were present in the
PTK2B and CHRNA2 genes, both of which are within 100–
125kb of the CLU gene (Supplementary Figure 7). Although
no SNP showed an association at P¼0.05 in the CLU gene,
severalSNPsdemonstratedthereportedtrendofassociation.
The 14 most signiﬁcant SNPs were present in the PTK2B
gene with Po4.0E–03. The top three SNPs in the PTK2B
Figure 1 Quantile-quantile plots showing the observed versus the expected P-values in the University of Pittsburgh sample including all single-nucleotide polymorphisms
(SNPs) (a) and after removing SNPs in the APOE, CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7 regions (b). The red line shows the
distribution under the null hypothesis.
Figure 2 Manhattan plots showing the genome-wide P-values in the University of Pittsburgh sample after adjusting for age (age-at-onset in cases), sex and principle
components. Red line indicates genome-wide signiﬁcant level (Po5E–08) and blue line indicates suggestive associations (Po1E–04) in the Pittsburgh sample.
Figure 3 Regional association plot on chromosome 19 including the best single-nucleotide polymorphism (SNP), rs429358 (E*4), for Alzheimer’s disease (AD) risk in the
University of Pittsburgh sample.
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Translational Psychiatrygene were rs373625 in intron 25 (P¼2.72E–03) and
rs9657295 and rs11135993 in intron 27 (P¼3.06E–03). The
reported associations in the CD2AP and CR1 genes were
not replicated in our sample, as signiﬁcant SNPs were
located B150kb from these two genes (Supplementary
Figures 8 and 9).
GWAS analysis. We next examined the entire GWAS data
set (B2.5 million SNPs) in the Pittsburg sample. Figure 1a
shows the comparison of observed P-values with the
P-values for a null distribution. The observed P-value con-
formed to the null distribution until the tail of the distribution
where it deviated, suggesting little evidence of stratiﬁ-
cation but compelling evidence of disease associations. As
expected, several SNPs in the APOE region on chromo-
some 19 demonstrated genome-wide signiﬁcant (Po5E–08)
associations (Figure 2). The most signiﬁcant SNP was
rs429358 (E*4) in the APOE gene (P¼2.52E–53) followed
by rs4420638 (P¼1.97E–42), rs6857 (P¼6.75E–38),
rs2075650 (P¼5.67E–29), rs157582 (P¼5.56E–28) and
rs157580 (P¼2.77E–10) in the APOE/APOC1/TOMM40
gene region. The regional association plot including all
SNPs in the APOE region is given in Figure 3.
After removing SNPs in the APOE, CR1, BIN1, CLU,
PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and
ABCA7 regions, a deviation of P-values from the null
distribution remained in the quantile-quantile plot, although
within the 95% conﬁdence interval of the expectation
(Figure 1b). Since no other SNPs outside the APOE region
were genome-wide signiﬁcant in the Pittsburgh discovery
sample, we performed a meta-analysis by combining the
results of the top B1% SNPs (B25000) with Po0.01 of the
discovery sample with the four existing data sets (2727 AD
cases and 3336 controls) for these SNPs. Of the known
loci, APOE, BIN1 and PICALM revealed genome-wide signi-
ﬁcant associations along with ﬁve suggestive new loci
with Po1E–05 in the meta-analysis (Table 1). All SNPs with
Po1E–04 in the meta-analysis are presented in Supple-
mentary Table.
Four of the top ﬁve SNPs outside the APOE and nine other
known loci were either directly genotyped or had proxy
genotyped SNPs with Po1E–04 on Illumina arrays (see
Table 1 and Supplementary Table), thus eliminating potential
spurious associations due to imputation artifact. The most
signiﬁcant SNP, rs3848140 (P¼3.05E–07), located in the
PPP1R3B (encoding protein phosphatase 1, regulatory
subunit 3B) region on chromosome 8 at position 9.04Mb
was actually genotyped and there were three additional
signiﬁcant SNPs in this gene at Po1E–06. The association of
this SNP with AD risk was consistent in all ﬁve samples with
meta odds ratio of 2.43. Figure 4 shows the regional plot
for SNPs within 500kb on either side of the PPP1R3B index
SNP and the meta P-values for markers which had PoIE–04
in the meta-analysis. The regional plots for the remaining four
top AD loci are shown in Supplementary Figures 10–13. To
remove any variation in AD due to the established effect of
APOE, we also analyzed the data after adjusting for the effect
of APOE*4, but found no appreciable difference in P-values
for the non-APOE loci (Table 1), indicating that their effects
are independent of APOE.
T
a
b
l
e
1
G
e
n
e
t
i
c
l
o
c
i
a
s
s
o
c
i
a
t
e
d
w
i
t
h
t
h
e
r
i
s
k
o
f
A
D
w
i
t
h
P
o
E
–
0
5
C
h
r
T
o
p
S
N
P
a
P
o
s
i
t
i
o
n
M
B
T
o
t
a
l
S
N
P
s
b
N
e
a
r
e
s
t
g
e
n
e
P
i
t
t
s
b
u
r
g
h
M
a
y
o
A
D
N
I
M
I
R
A
G
E
U
M
/
V
U
/
M
S
S
M
M
e
t
a
-
a
n
a
l
y
s
i
s
M
e
t
a
A
P
O
E
a
d
j
u
s
t
e
d
P
H
e
t
e
r
o
g
e
n
e
i
t
y
t
e
s
t
(
I
)
O
R
P
O
R
P
O
R
P
O
R
P
O
R
P
O
R
P
1
9
r
s
4
4
2
0
6
3
8
5
0
.
1
1
2
8
(
1
4
)
A
P
O
E
/
T
O
M
M
4
0
/
A
P
O
C
1
0
.
3
2
1
.
9
7
E
–
4
2
0
.
2
1
1
.
7
2
E
–
5
1
0
.
2
8
2
.
1
1
E
–
0
6
0
.
3
8
6
.
4
4
E
–
2
2
0
.
2
5
7
.
3
8
E
–
3
8
0
.
2
9
7
.
9
1
E
–
1
4
9
1
.
9
9
E
–
1
1
7
9
.
3
1
2
r
s
7
5
6
1
5
2
8
1
2
7
.
6
1
2
(
1
)
B
I
N
1
1
.
2
7
2
.
9
6
E
–
0
4
1
.
2
6
1
.
0
7
E
–
0
3
1
.
3
4
9
.
0
5
E
–
0
2
1
.
1
4
8
.
6
6
E
–
0
2
1
.
2
9
9
.
9
4
E
–
0
5
1
.
2
5
6
.
0
0
E
–
1
1
4
.
8
0
E
–
0
9
0
1
1
r
s
1
7
8
1
7
6
0
0
8
5
.
3
6
3
0
(
7
)
P
I
C
A
L
M
1
.
4
1
3
.
6
7
E
–
0
4
1
.
3
6
2
.
3
1
E
–
0
3
0
.
9
4
8
.
4
8
E
-
0
1
1
.
3
8
1
.
2
2
E
–
0
2
1
.
2
5
2
.
1
2
E
–
0
2
1
.
3
3
2
.
1
7
E
–
0
8
1
.
4
0
E
–
0
5
0
8
r
s
3
7
4
8
1
4
0
9
.
0
4
4
(
2
)
P
P
P
1
R
3
B
2
.
8
0
5
.
7
5
E
–
0
4
3
.
4
7
6
.
5
7
E
–
0
3
1
0
.
1
4
1
.
3
1
E
–
0
1
1
.
6
2
1
.
8
2
E
–
0
1
2
.
2
4
1
.
4
8
E
–
0
2
2
.
4
3
3
.
0
5
E
–
0
7
4
.
9
3
E
–
0
6
0
1
1
r
s
1
2
8
0
8
1
4
8
1
0
2
.
2
4
1
(
0
)
M
M
P
3
/
M
M
P
1
2
0
.
7
6
1
.
3
8
E
–
0
3
0
.
8
2
4
.
5
5
E
–
0
2
0
.
6
2
5
.
6
0
E
–
0
2
0
.
8
7
1
.
3
9
E
–
0
1
0
.
8
2
1
.
5
5
E
–
0
2
0
.
8
1
1
.
2
4
E
–
0
6
1
.
0
2
E
–
0
5
0
4
r
s
6
8
5
6
7
6
8
3
0
.
0
8
4
(
1
)
—
0
.
8
2
3
.
1
1
E
-
0
3
0
.
8
1
3
.
0
5
E
–
0
3
0
.
9
7
8
.
5
5
E
–
0
1
0
.
8
8
1
.
2
1
E
–
0
1
0
.
8
9
8
.
1
9
E
–
0
2
0
.
8
5
4
.
6
3
E
–
0
6
8
.
2
2
E
–
0
5
0
5
r
s
1
1
7
3
8
3
3
5
6
0
.
9
9
9
(
3
)
F
L
J
3
7
5
4
3
0
.
7
5
5
.
7
2
E
.
0
4
0
.
8
6
6
.
8
3
E
–
0
2
1
.
1
9
4
.
3
9
E
–
0
1
0
.
8
4
5
.
6
2
E
–
0
2
0
.
8
3
1
.
7
3
E
–
0
2
0
.
8
3
4
.
6
6
E
–
0
6
4
.
2
8
E
–
0
6
3
.
4
3
2
r
s
1
3
5
7
6
9
2
1
0
7
.
0
4
1
1
(
1
)
—
0
.
8
2
4
.
6
3
E
–
0
3
0
.
8
7
4
.
8
2
E
–
0
2
1
.
0
5
7
.
8
9
E
–
0
1
0
.
8
2
1
.
6
7
E
–
0
2
0
.
8
8
5
.
1
7
E
–
0
2
0
.
8
6
9
.
2
7
E
–
0
6
3
.
2
8
E
–
0
6
0
A
b
b
r
e
v
i
a
t
i
o
n
s
:
A
D
N
I
,
A
l
z
h
e
i
m
e
r
’
s
D
i
s
e
a
s
e
N
e
u
r
o
i
m
a
g
i
n
g
I
n
i
t
i
a
t
i
v
e
;
A
P
O
E
,
a
p
o
l
i
p
o
p
r
o
t
e
i
n
E
;
M
B
,
m
e
g
a
b
a
s
e
;
O
R
,
o
d
d
s
r
a
t
i
o
;
S
N
P
,
s
i
n
g
l
e
-
n
u
c
l
e
o
t
i
d
e
p
o
l
y
m
o
r
p
h
i
s
m
;
U
M
/
V
U
/
M
S
S
M
,
U
n
i
v
e
r
s
i
t
y
o
f
M
i
a
m
i
/
V
a
n
d
e
r
b
i
l
t
U
n
i
v
e
r
s
i
t
y
/
M
t
.
S
i
n
a
i
S
c
h
o
o
l
o
f
M
e
d
i
c
i
n
e
.
a
S
N
P
w
i
t
h
t
h
e
l
o
w
e
s
t
P
-
v
a
l
u
e
i
n
a
g
i
v
e
n
g
e
n
e
r
e
g
i
o
n
a
f
t
e
r
m
e
t
a
-
a
n
a
l
y
s
i
s
.
b
T
o
t
a
l
g
e
n
o
t
y
p
e
d
o
r
i
m
p
u
t
e
d
s
i
g
n
i
ﬁ
c
a
n
t
S
N
P
s
w
i
t
h
P
o
1
E
–
0
4
i
n
a
g
i
v
e
n
r
e
g
i
o
n
a
f
t
e
r
m
e
t
a
-
a
n
a
l
y
s
i
s
.
T
h
e
n
u
m
b
e
r
o
f
g
e
n
o
t
y
p
e
d
S
N
P
s
i
s
g
i
v
e
n
i
n
p
a
r
e
n
t
h
e
s
e
s
.
GWAS of AD
MI Kamboh et al
5
Translational PsychiatryDiscussion
In this study, we have used a new GWAS data set to (i)
examineindetailtherecentlyimplicatedninenewregionswith
AD risk,and to(ii) perform a meta-analysisutilizing thetop 1%
GWAS SNPs (B25000) with Po0.01 along with four
independent data sets for these SNPs in an effort to identify
new AD loci.
Five of the nine loci are replicated in the Pittsburgh sample
as we found multiple nominal signiﬁcant SNPs in or around
ﬁve genes (PICALM, BIN1, ABCA7, MS4A4/MS4A6E and
EPHA1), suggesting that these are the relevant genes for AD
in these regions. As associations in these genes have been
validated in multiple studies,
13,16 it is acceptable to consider
Po0.05 statistically signiﬁcant infollow-up studies
24like ours.
However, the identity of the potential causal genes in the
remaining four regions (CD33, CLU, CD2AP and CR1) is not
clear in the Pittsburgh sample, as signiﬁcant SNPs were
observed 69–180kb outside of these genes. The power in our
Pittsburgh sample to detect these nine loci for the effect sizes
reported in a previous GWAS
16 is 0.38, 0.43, 0.39, 0.31, 0.38,
0.30, 0.28, 0.28 and 0.47 for PICALM, BIN1, ABCA7, MS4A4,
EPHA1,CD33,CLU,CD2APandCR1,respectively.Although
the overall power is low and this would reduce our conﬁdence
in our negative results, it enhances the interest in our positive
results even further.
There were only 11 SNPs present in the CD33 gene on the
1M chip. This may explain why we did not observe any
signiﬁcant SNP in this gene, although the reported genome-
wide signiﬁcant SNP (rs3865444) gave a P-value of 0.25 with
the same effect size in our sample. Also, recombination is low
in the CD33 region; thus, it is likely that functional SNPs may
bepresentinabroaderregionaroundCD33.Althoughnoneof
the small number of 15 SNPs present in the CLU gene on the
1M chip showed signiﬁcant association at Po0.05, a number
of them showed the trend of association reported in earlier
studies. However, several SNPs in a nearby PTK2B gene
that is expressed in adult brain,
25 revealed signiﬁcant
associations. Perhaps, genetic variations in the CLU and
PTK2B genes, both of which are expressed in the brain, are
relevant to AD risk and thus resequencing a broader region in
and around these genes may reveal functional variants.
However, a recent sequencing study found no functional
SNPs in the coding region of the CLU gene and, likewise, no
signiﬁcant association was found between the previously
associated CLU SNPs with AD risk with expression quanti-
tative trait loci,
26 suggesting that the biological role of CLU is
AD is not yet clear. While ﬁndings in our sample suggest the
involvement of broader regions around the CD33 and CLU
genes, the evidence of association of the CR1 and CD2AP
with AD is weak or absent.
The GWAS analysis in the Pittsburgh data set found only
the APOE/TOMM40/APOC1 region to be genome-wide
signiﬁcant, which is due to the established association with
the APOE*4 SNP. Meta-analysis of the top 25000 SNPs from
the Pittsburgh GWAS data, in conjunction with four repli-
cation data sets revealed ﬁve suggestive non-APOE loci.
The top SNP was located in the PPP1R3B gene, which is a
potential candidate gene for AD as it is expressed in human
brain.
27 Genetic variation in PPP1R3B has been shown to be
associated with plasma high density lipoprotein and choles-
terol levels and the risk of coronary artery disease.
28,29
OverexpressionofthemouseorthologPpp1r3binmouseliver
results in signiﬁcantly lower high density lipoprotein levels.
28
As high density lipoproteins levels and particle size affect the
clearance of b-amyloid in mouse brain,
30 it is conceivable
that the PPP1R3B-associated effect on AD risk is mediated
through its impact on high density lipoproteins levels.
Although the association of the top PPP1R3B SNP did not
meet the strict criteria for genome-wide signiﬁcance, it was
consistent in direction in all samples as reﬂected in Odds ratio
values (see Table 1). This suggests that this gene region
should be followed up in additional samples. If these ﬁndings
are conﬁrmed, then this would be another cholesterol-related
gene involved in AD along with APOE, CLU and ABCA7.
Figure 4 Regional association plot on chromosome 8, including the best single-nucleotide polymorphism (SNP) (rs3748140) for Alzheimer’s disease (AD) risk in the
PPP1R3B gene in the Pittsburgh sample (blue triangles), and meta-analysis (red dots).
GWAS of AD
MI Kamboh et al
6
Translational PsychiatryIn conclusion, 6 of the 10 established AD loci, including the
APOElocus,havebeenreplicatedinour newGWASdata set,
whilebroaderregionsintheremainingfourlociaresuspected.
Although we did not identify additional non-APOE SNPs
meeting a conservative threshold of genome-wide signiﬁ-
cance, we have identiﬁed ﬁve suggestive loci that warrant
follow-up in additional samples.
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